Vertex Pharmaceuticals (NQ:VRTX)

487.33 +3.30 (+0.68%)

Streaming Delayed Price Updated: 9:46 AM EDT, Aug 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

75 76 Next >

Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy? ↗

February 08, 2024

Its pain medicine isn't precisely what it hoped for, but it could still sell.

Via The Motley Fool

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗

February 07, 2024

Via Benzinga

Vertex's Next-Generation Cystic Fibrosis Program Shows Efficacy With Reduced Burden, Provides Growth Opportunity: Goldman Sachs ↗

February 06, 2024

Vertex Pharmaceuticals' cystic fibrosis treatment with vanza triple therapy. SKYLINE trials show non-inferiority to Trikafta, emphasizing once-daily dosing benefits.

Via Benzinga

Vertex Pharmaceuticals' Triple Combo Treatment For Lung Disorder Meets Primary Goal In Adult And Pediatric Patients ↗

February 06, 2024

Vertex Pharmaceuticals' vanza triple program for cystic fibrosis, with superior results in lung function, sweat chloride reduction, and safety.

Via Benzinga

Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can Invest ↗

February 06, 2024

Its foray into developing analgesics seems to be going swimmingly.

Via The Motley Fool

Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 06, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

This High-Flying Stock Just Got Some Bad News: Should You Sell? ↗

February 06, 2024

It's just a minor setback for this leading biotech.

Via The Motley Fool

Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat ↗

February 05, 2024

The company also topped fourth-quarter expectations.

Via Investor's Business Daily

The 7 Best Healthcare Stocks to Invest In for Big Gains in 2024 ↗

February 06, 2024

Invest in the future with healthcare stocks 2024; offering a blend of market stability and cutting-edge medical advancements.

Via InvestorPlace

Vertex Pharmaceuticals (VRTX) Q4 2023 Earnings Call Transcript ↗

February 05, 2024

VRTX earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Vertex Reports Fourth Quarter and Full Year 2023 Financial Results

February 05, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis

February 05, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Earnings Preview: Vertex Pharmaceuticals ↗

February 02, 2024

Via Benzinga

Key Takeaways From Vertex Pharmaceuticals Analyst Ratings ↗

January 31, 2024

Via Benzinga

Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday? ↗

February 05, 2024

Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed officials' comments push stocks into red, reducing rate cut expectations for...

Via Benzinga

Topics Economy

Vertex Pharmaceuticals Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

February 05, 2024

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is expected to release earnings results for its fourth quarter, after the closing bell on Feb. 5, 2024.

Via Benzinga

Will Jerome Powell Spoil Wall Street's Party? US Stock Futures Slip As Fed Chief Maintains Hawkish Tone Ahead Of More Earnings ↗

February 05, 2024

As the market pushes higher despite the Federal Reserve's non-committal stance, traders fear a potential drawdown.

Via Benzinga

Topics Economy

Earnings Scheduled For February 5, 2024 ↗

February 05, 2024

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is estimated to report quarterly earnings at $0.26 per share on revenue of $43.92 million.

Via Benzinga

Investor Optimism Improves Following Tech Earnings, Jobs Data; S&P 500 Gains For 4th Week ↗

February 05, 2024

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the "Greed" zone on Friday. U.S. stocks closed higher on Friday, with the S&P 500...

Via Benzinga

Topics Stocks

Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 3 ↗

February 03, 2024

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of Jan. 29 through Feb. 2.

Via Talk Markets

Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy? ↗

February 02, 2024

Vertex shares recently reached an all-time high.

Via The Motley Fool

Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗

February 02, 2024

The Dow led the major indexes higher. Big techs diverged on results.

Via Investor's Business Daily

Topics Economy Stocks

Should Quality Investors Include NASDAQ:VRTX in Their Portfolio? ↗

February 02, 2024

In this article we'll explore the quality characteristics of VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)

Via Chartmill

Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements ↗

February 01, 2024

Discover how emerging tech is shaping healthcare stocks in 2024. See which companies are outperforming and what it means for your portfolio.

Via InvestorPlace

Biotech And Medtech Portfolio Notes On A Fed Day ↗

January 31, 2024

The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23%

Via Talk Markets

Topics Economy

Buy Alert: 3 Stocks Sitting in the Sweet Spot ↗

January 31, 2024

They say timing is everything, so investors will want to take advantage of buying these stocks now instead of waiting.

Via InvestorPlace

Why Vertex Pharmaceuticals Stock Topped the Market Today ↗

January 30, 2024

The company reported that it met its primary endpoint in a study for its non-opioid pain drug.

Via The Motley Fool

Why Is Vertex Pharmaceuticals Stock Sliding Today? ↗

January 30, 2024

Explore Vertex Pharmaceuticals' Phase 3 results for VX-548, a NaV1.8 inhibitor, demonstrating significant pain relief post-surgery.

Via Benzinga

Vertex Skids — Its Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst ↗

January 30, 2024

The company unveiled the results of Phase 3 testing in patients following a tummy tuck or bunion removal.

Via Investor's Business Daily

Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain

January 30, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.